Vascular calcification is believed to have a crucial role in the excess cardiovascular mortality and morbidity in patients with end-stage renal disease (ESRD). Recent evidence suggests that uraemic vascular calcification is an active cellmediated process [1] . An epidemiological study observed an association between lipid-lowering therapy and vascular calcification [2] . However, no prospective investigation has been published to prove an effect of lipid-lowering therapy on the progression of vascular calcification in patients with ESRD.
We therefore conducted the present study that prospectively compared the rate of change in the amount of vascular calcification before and during lipid-lowering therapy in haemodialysis patients. The aortic calcification index (ACI) was estimated by computed tomography (CT) as described previously [3] . At the time of the first CT, fasting lipid levels as well as serum levels of calcium (Ca) and phosphorus levels were measured and lipid-lowering therapy with colestimide (1.5 g/day) and atorvastatin (10 mg/day) was initiated. Patients were instructed to keep any other medical therapy unchanged.
A total of 29 patients completed the protocol and could be evaluated. Progression of aortic calcification was significantly less pronounced during treatment with colestimide and atorvastatin compared with the period before treatment was initiated. The mean ACI in the first CT was 35.6±20.2%. The median ACI in the second CT, after an average interval of 22.9±3.2 months on treatment, was 29.0±16.2% (P<0.05). Average total cholesterol and LDL cholesterol levels in the untreated period were 246±38 and 156±41 mg/dl, respectively. A mean reduction of 21 (total cholesterol) and 44% (LDL cholesterol) was achieved. Triglyceride levels fell by 25%. Serum phosphorus levels decreased significantly with the treatment from 6.8±1.4 to 5.4±1.2 mg/dl, whereas serum Ca levels showed no significant difference (9.8±0.6 vs 9.6±0.8 mg/dl).
Our preliminary, uncontrolled investigation is the first report that prospectively examines the influence of both colestimide and atorvastatin on the progression of vascular calcification in haemodialysis patients. It is unclear how changes in aortic calcification were achieved by lipid-lowering therapy. One possible explanation is that colestimide acts as a bile acid sequestrant and is therefore capable of reducing serum phosphorus levels as described previously [4] , and that atorvastatin and colestimide significantly reduced LDL cholesterol levels. A randomized, placebo-controlled study is required to determine whether colestimide and atorvastatin inhibit vascular calcification in patients with ESRD. Combination of intermittent haemodialysis and high-volume continuous haemofiltration for the treatment of severe metformin-induced lactic acidosis
Sir, Metformin has been used for many decades as an effective glucose-lowering medication in the treatment of type 2 diabetes mellitus. Recent studies clearly demonstrated that metformin reduced secondary complications of diabetes mellitus type 2 without promoting weight gain, which is in contrast to treatment with insulin and/or sulphonylurea [1] . Lactic acidosis is a serious side effect observed with metformin treatment and an incidence rate of 9 lactic acidoses per 100 000 person-years of metformin treatment, as has been calculated [2] . This side effect is usually found in patients receiving metformin despite major contraindications, such as renal insufficiency and/or cardiopulmonary instability. The mortality in metformin-induced lactic acidosis is very high and has been estimated to be >50% [3] . Only a small number of cases of metformin overdoses with lactic acidosis have been described in the literature [4] . We report the case of a patient with severe lactic acidosis and cardiocirculatory arrest caused by metformin intoxication. Despite a plasma metformin concentration of 191 mg/l (to our knowledge the highest reported value in the literature), the patient recovered totally after treatment with a combination of intermittent haemodialysis and high-volume continuous haemofiltration.
A 42-year-old man was admitted with nausea and vomiting. The patient declared that he wanted to kill himself, but denied that he had taken any medications or drugs. His past medical history included type 2 diabetes that was treated with initial unknown types of oral hypoglycaemics. On admission, the patient was in a stable condition and initial routine laboratory workup was normal.
Four hours later, the patient complained of severe dyspnoea. Laboratory studies revealed a metabolic acidosis (pH 7.20, pCO 2 37 mmHg, bicarbonate 15.8 mmol/l, anion gap 18) and a lactate concentration of 8.9 mmol/l. The patient was transferred to the intensive care unit (ICU), where he developed respiratory insufficiency and severe hypotension, resulting in intubation, mechanical ventilation and administration of dopamine and noradrenaline infusion. Laboratory workup showed further progression of the lactic acidosis (pH 6.89, pCO 2 30 mmHg, bicarbonate 6.7 mmol/l, lactate 21.6 mmol/l) and a serum creatinine of 1.8 mg/dl. Urine analysis was negative for ketones.
In the meantime, a relative reported that metformin is part of the patient's medication. This information in combination with the patient's initial declaration of intending to harm himself led to the assumption of a metformin-induced lactic acidosis.
We started intermittent haemodialysis for 11 h (with 1 h interruption) in order to remove metformin and lactate as fast as possible and to correct acidosis. However, blood lactate levels remained very high and progressive haemodynamic instability occurred. Haemodialysis treatment was stopped and continuous veno-venous haemofiltration (CVVH) with bicarbonate substitute was started. Because of a further rise in the lactate level (25.8 mmol/l) and the poor clinical course of the patient, we intensified the extracorporeal elimination treatment using a second CVVH machine with a femoral catheter access. Under this 
